Based on the above principles, three ICI-based immune combination therapies, dual immunotherapy, ICI+anti-VEGFR/VEGFA, and ICI + MKI, have become research hotspots for HCC treatment. The gene discussed is KDR; the disease is hepatocellular carcinoma.